As reported in Korea Biomedical Review, writer Lee Hye-seon reports that The Ministry of Food and Drug Safety, Korean has approved a 3a clinical trial for “semaglutide” (for injection) sponsored by Novo Nordisk. Branded as Ozempic, it is the company’s new GLP (glucagon-like peptide)-1 analog and a drug to treat type 2 diabetes through a weekly dose.

Ozempic received approval in the United States in late 2017. See the here for more information.

Source: Korea Biomedical Review

Pin It on Pinterest